Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label single-arm study of isosulfan blue injection for sentinel lymph node mapping in early breast cancer
CTR20255157Phase 3Active
- Sponsor
- China Medical System Holdings Limited
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of isosulfan blue in breast cancer, sponsored by China Medical System Holdings Limited. Started Apr 2026; status: active.
02
Drugs
isosulfan blue
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20255157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20255157.